X

Trial Profile

A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary)
Indications Leiomyosarcoma; Nerve sheath neoplasms; Sarcoma; Soft tissue sarcoma
Focus Adverse reactions
Acronyms METSSAR

Most Recent Events

15 Mar 2024 Status changed from recruiting to active, no longer recruiting.
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
07 Jun 2022 Results (n=19) assessing safety and tolerability of split-dose selinexor in patients with advanced soft tissue sarcoma , presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com